New hope for liver cancer: combo therapy outperforms standard care?
NCT ID NCT04720716
First seen Mar 19, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study tested a combination of two drugs (IBI310 and sintilimab) against the standard drug sorafenib in 344 people with advanced liver cancer who had not received prior treatment. The goal was to see if the combo helped patients live longer or shrink tumors more effectively. While the treatment aims to control the disease, patients may need ongoing therapy, so it is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan Universtiy Zhongshan Hospital
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.